Mergers & Acquisitions

• Tiantu Capital in the approximately US$226 million sale of its entire interest in Yoplait China to Kunshan Nuoyuan Ruiyuan Management Consulting Co., Ltd.
• Acotec Scientific in its approximately US$520 million voluntary partial offer by Boston Scientific
• China VAST Industrial Urban Development (6166.HK) and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited (817.HK)
• Global Infrastructure Solutions Inc. in multiple matters, including in its strategic merger with J. Roger Preston, a construction consulting company with offices in Hong Kong and Southeast Asia, and the strategic acquisition of Arcadis’s Hong Kong and projects and consulting company in Singapore
• SEEK Limited in its multiple investment, acquisition and assets placement in North and South America
• Chun Yip International Investment Ltd. in the takeover of controlling stakes of Golden Ponder Holdings Limited (1783.HK)
• China VAST Industrial Urban Development Company Limited and its major shareholder in the sale of approximately US$191 million of shares to China Jinmao Holdings Group Limited, and the issuance of 6% convertible bonds of US$123 million with a 36 month maturity date to China Jinmao
• Viva Biotech in its US$387.3 million acquisition of Langhua Pharmaceutical and US$135.4 million share placement
• Warner Brothers in its sale of equity in the joint venture, Flagship Entertainment Group, to CMC Capital
• The controlling shareholder of Central China Real Estate (0832.HK) in the US$83 million acquisition of the second largest shareholder's entire interest in Central China Real Estate
• China International Marine Containers in its spin-off sale of Pteris Global Limited to its China Fire Safety Enterprise Group (0445.HK)
• Joy Bright Investments in its US$233 million acquisition of the entire equity interests in Tianjin China Minsheng Drawin Technology Limited from China Minsheng Investment Group Corp., Ltd.
• Numerous international private equity and investment institutions in equity investment, placement and allocation

Public Offering Transactions

• Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited as joint sponsors and the underwriters in the IPO and listing of Shenzhen Medcaptain Medical Technology Co., Ltd. (2041.HK) on the Hong Kong Stock Exchange
• Macquarie as overall coordinator in:
• the approximately US$370 million share placement for Time Interconnect Technology Limited (1729.HK)
• the approximately US$210 million share placement for Time Interconnect Technology Limited
• Pharmaron Beijing Co., Ltd. (3759.HK) in:
• approximately US$588 million dual primary listing and H share offering in Hong Kong
• US$600 million zero coupon convertible bonds offering
• approximately US$171 million placing of new H shares under general mandate
• TransThera Sciences (Nanjing), Inc. (2617.HK) in its approximately US$24 million placing of new H shares under general mandate
• Ruichang International Holdings Limited (1334.HK) in its approximately US$17 million IPO and listing on the Hong Kong Stock Exchange
• eHi Car Services in:
• US$325 million Regulation S high-yield bond offering due 2027
• US$152 million bond exchange offer and exit consent solicitation
• CICC, CCB, CMB, CMS and other underwriters in the approximately US$150 million IPO of Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) on the Hong Kong Stock Exchange
• Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
• Yonghe Medical Group Co., Ltd. in its US$206 million IPO and listing on the Hong Kong Stock Exchange
• Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
• J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
• Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
• Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
• Akeso Biopharma in its US$383 million IPO and listing on the Hong Kong Stock Exchange
• Viva Biotech in its US$194 million IPO on the Main Board of the Hong Kong Stock Exchange
• Hua Medicine in its US$110 million IPO on the Main Board of the Hong Kong Stock Exchange
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange